Gabapentinoid use in French most precarious populations: Insight from Lyon Permanent Access to Healthcare (PASS) units, 2016-1Q2021.

Mathieu Chappuy Mikail NourredineBertrand ClercMorgan FahmiPauline MisslinMaude BerthierLouise LaloiBenjamin Rolland

Published in: Fundamental & clinical pharmacology (2021)

Our study reveals a local but substantial increase in gabapentinoid use in populations with no social insurance. These findings should be confirmed more widely and plead for the systematic collection of anonymous patient data in free healthcare centers in France.

Keyphrases

healthcare
case report
electronic health record
mental health
affordable care act
genetic diversity
health insurance
data analysis
artificial intelligence
deep learning